Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone  by Nagler, Arnon et al.
Kidney International, Vol. 52 (1997), pp. 1561—1569
Inhibition of glomerular mesangial cell proliferation and
extracellular matrix deposition by halofuginone
ARNON NAGLER, Avi KATZ, HELENA AINGORN, HUA-QUAN MIAo, REBA C0NDI0TTI, OLGA GENINA,
MAIx PINES, and ISRAEL VLODAVSKY
Department of Bone Marrow Transplantation, Hadassah-Hebrew University Hospital, and Department of Pediatrics, Bikur Holim
Hospital, Jerusalem; Department of Oncology, Hadassah-Hebrew University Hospital, and Institute of Animal Science, Agricultural
Research Organization, The Volcani Center, Bet Dagan, Israel
Inhibition of glomerular mesangial cell proliferation and extracellular
matrix deposition by halofuginone. Mesangial cell proliferation, increased
deposition of collagen, and expansion of the mesangial extracellular
matrix (ECM) are key features in the development of mesangioprolifera-
tive diseases. Halofuginone, a low molecular weight anti-coccidial quino-
azolinone derivative, inhibits collagen type al(l) gene expression and
synthesis. We investigated the effect of halofuginone on both normal and
SV40 transformed mesangial cell proliferation, collagen synthesis, and
ECM deposition. Proliferation of both cell types was almost completely
inhibited in the presence of 50 ng/ml halofuginone. The cells were arrested
in the late G1 phase of the cell cycle and resumed their normal growth rate
following removal of the compound from the culture medium. The
antiproliferative effect of halofuginone was associated with inhibition of
tyrosine phosphorylation of cellular proteins. Similar results were ob-
tained whether the mesangial cells were seeded on regular tissue culture
plastic or in close contact with a naturally produced ECM resembling their
local environment in vivo. Halofuginone also inhibited synthesis and
deposition of ECM by mesangial cells as indicated by a substantial
reduction in 4C-glycine and Na235504 incorporation into the ECM, and
by the inhibition of collagen type I synthesis and gene expression. It is
proposed that by inhibiting collagen type I synthesis and matrix deposi-
tion, halofuginone exerts a potent antiproliferative effect that may be
applied to inhibit mesangial cell proliferation and matrix expansion in a
variety of chronic progressive glomerular diseases.
Mesangial cell (MC) proliferation is a key feature of glomeru-
lopathies such as IgA nephropathy, lupus nephritis, Schönlein-
Henoch purpura, and membranoproliferative glomerulonephritis
[1,2]. In addition, expansion of the mesangium due to increases in
cellularity and/or extracellular matrix (ECM) is a feature of many
advanced glomerular lesions and is particularly prominent in
diabetic nephropathy and glomerular sclerosis [3—10]. The ability
to attenuate MC proliferation and matrix deposition is therefore
expected to halt the progression to end-stage renal disease
occurring in the context of the histopathologic lesions of several
mesangioproliferative diseases. It is thus not surprising that
modulation of MC growth both in vitro and in vivo has become the
focus of intense research efforts. While several mitogens stimulate
MC proliferation in vitro, only a few substances, primarily heparin
and heparan sulfate, exert an antiproliferative effect on cultured
mesangial cells [11]. The use of heparin, however, for the treat-
ment of human glomerular diseases has never gained acceptance
[8, 12, 13].
Mesangioproliferative diseases resemble in some aspects the
process of atherosclerosis [14]. In both, the participant cells are
vascular endothelial cells and the underlying vascular smooth
muscle cells, or their renal counterpart, the mesangial cells.
Smooth muscle cells and MCs are closely related in terms of
origin, microscopic anatomy, and histochemical characteristics
[15]. Increased amounts of types I, III and IV collagens and
expansion of the mesangial ECM either precede or accompany
the process of human glomerular sclerosis and interstitial fibrosis
[16—19]. In fact, collagens and other ECM components regulate
mesangial cell proliferation and differentiation [18, 19]. We have
recently demonstrated that inhibition of collagen type I synthesis
is associated with a profound suppression of vascular smooth
muscle cell proliferation [20]. This inhibition was efficiently
brought about by halofuginone, a potent inhibitor of collagen
al(I) gene expression and synthesis [21, 22]. This low molecular
weight (molecular wt = 495), non-toxic alkaloid compound was
originally isolated from the plant Dichroa febnfuga and is com-
monly used as a coccidiostat in chickens and turkeys [22].
Halofuginone effectively inhibited proliferation of vascular
smooth muscle cells associated with anastomotic [23] and injury-
induced [20] intimal hyperplasia in experimental animal models.
It also abrogated collagen type I synthesis and fibrosis in chronic
graft versus host disease and scleroderma [24, 25], as well as in
lung and liver fibrosis, both in vitro and in vivo [26, 27]. In view of
these findings, we assessed the effect of halofuginone on prolif-
eration and collagen al(I) synthesis and gene expression by
glomerular MCs in vitro [28, 29].
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METHODS
Materials
Dulbecco's modified Eagle's medium (DMEM, 4.5 g glucose/
liter), RPMI, Ham's F-12 medium, calf serum, fetal calf serum
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(FCS), penicillin, streptomycin and saline containing 0.05% tryp-
sin, 0.01 M sodium phosphate (pH 7.4) and 0.02% EDTA (trypsin/
EDTA) were obtained from Biological Industries (Beit-Haemek,
Israel). Recombinant human basic FGF (bFGF) was kindly
provided by Dr. Peter Bohlen (Lederle Laboratories, Pearl River,
NY, USA). Tissue culture dishes were obtained from Falcon
Lahware Division, Becton Dickinson (Oxnard, CA, USA). Twen-
ty-four-well plates were from Nunc (Rosklide, Denmark).
Halofuginone was a generous gift of Roussel UCLAF (Paris,
France). Rat pro-csl(I) and -al(11I) collagen cDNA was kindly
provided by Dr. BE. Kream, University of Connecticut Health
Center (Farmington, CT, USA). Sodium heparin from porcine
intestinal mucosa (Avg. Mr 14,000; anti-factor Xa 165 lU/mg) was
obtained from Hepar Industries (Franklin, OH, USA); 2,3,4,5-3H-
L-proline (122 Ci/mmol), 14C- glycine (100 mCi/mmol), and
Na235SO4 (540 to 590 mCi/mmol) were purchased from New
England Nuclear (Boston, MA, USA). Type IV collagenase and
Dextran T-40 were obtained from Sigma Chemical Co. (St. Louis,
MO, USA).
Cells
Rat mesangial cells (RMC) were established in culture as
previously described [281. Briefly, glomeruli were prepared from
Wistar rats, washed (X3) in phosphate-buffered saline (PBS) and
resuspended in the same buffer containing 1 mg/mI bacterial
collagenase (type IV; 750 U/mI). After 15 to 30 minutes at 37°C
the suspension was centrifuged at 50 g for five minutes, the
pelleted glomerular cores washed in PBS, and finally resuspended
in minimal essential medium containing 20% heat-inactivated
FCS, 2 mvt L-glutamine, 10 jig/mI transferrin, 0.6 IU/ml insulin, 5
ng/ml sodium selenite, 100 lU/mi penicillin, 100 jig/mI streptomy-
cm, and 14 mivi HEPES, pH 7.2. Cells were maintained at 37°C in
95% air and 5% CO2 humidified environment. Cell outgrowth
occurred within 3 to 5 days, reaching confluence after 14 to 21
days. Cells were characterized by (i) morphological appearance of
stellate to fusiform cells, (ii) immunofluorescence staining of actin
and myosin fibers, and (iii) immunofluorescence staining for type
IV collagen, fibronectin, laminin and basement membrane chon-
droitin sulfate proteoglycan [281. Immunofluorescence staining
was negative for the common leukocyte antigen, Ia surface
antigen and factor VIII. Cells were cultured in 1:1 DMEM (4.5 g
glucose/liter):F-12 medium supplemented with 10% FCS, pas-
saged with trypsin/EDTA and used between the 3rd and the 10th
passages. A mouse glomerular MC line (SV4O MES 13) was
obtained from American Type Culture Collection (ATCC) and
maintained in culture as described above. This cell line was
established from a 7- to 10-week old C57BL/6J x SJL/J mouse
transgenic for the early region of simian virus 40 (SV4O) [29j.
Despite their transformed phenotype, the MES mouse cells
maintain features of normal glomerular mesangial cells and do
not express cytokeratin and factor VIII related antigen [29].
Mesangial cell extracellular matrix synthesis and deposition
Rat mesangial cells were dissociated from stock cultures (2nd to
5th passages) with trypsin/EDTA and plated into four-well plates
at a density of 1 x io cells/well. Cells were maintained as
described above, except that 5% dextran T-40 was included in the
growth medium [20, 30]. Five to six days after seeding, the
underlying ECM was exposed by dissolving (3 mm, 22°C) the cell
layer with a solution containing 0.5% Triton X-100 and 20 mM
NH4OH in PBS, followed by four washes in PBS [30]. The ECM
remained intact and attached to the entire area of the tissue
culture dish [301. Rat MCs were seeded into 24-well plates at a
confluent cell density (5 >< i05 cells/16 mm well/mi). Halofuginone
and either Na235SO4 (40 jiCi/ml) or '4C-glycine (5 jiCi/ml) were
added on days I and 3. Control cells were maintained in the
absence of halofuginone. On day 6, the cell layer was solubilized
to expose the underlying ECM, as described above. To determine
the amount of collagenase digestible (CDP) and trypsin digestible
proteins, the ECM was washed and digested with collagenase
(type IV, 20 U/mI, 18 hr, 37°C; Sigma) or trypsin (25 j.tg/ml, 24 hr,
37°C) and the amount of ECM incorporated sulfate and glycine
determined by /3-scintillation counting [20—22].
Cell proliferation
Cell proliferation was evaluated by cell counting. Mouse MES
cells and rat MCs (RMCs) were plated (1.5 X i0 cells/35 mm dish
and 5 X l0/16 mm well, respectively) in a 1:1 mixture of DMEM
and F-12 medium supplemented with 5% FCS. Twenty-four hours
after seeding the cells were exposed to increasing concentrations
of halofuginone (added once) and at various time intervals the
cells were dissociated with trypsin/EDTA and counted in a
Coulter counter (Coulter Electronic Ltd., Harpenden, Herts, UK)
[20]. Each of the cell proliferation experiments was performed at
least three times and the variation between different experiments
did not exceed 20%.
FACScan analysis of DNA content
Cells grown for 48 hours were trypsinyzed, washed with cold
PBS and fixed with ethanol for one hour at —20°C. Subsequently,
cells were centrifuged, resuspended in cold PBS and stained for 15
minutes with 50 jig/mi propidium iodide in the presence of RNase
A at a final concentration of 10 jig/ml. Cells were analyzed in a
fluorescence-activated cell sorter (FACScan; Becton Dickinson,
Santa Clara, CA, USA).
Tyrosine phosphorylation
Rat MCs were sparsely seeded on gelatin coated 10-cm dishes.
Subconfluent cultures were either maintained in DMEM (4.5 g
glucose/liter) containing 10% FCS or starved by 48 hours incuba-
tion in DMEM containing 0.5% FCS followed by 10 minutes
stimulation with 10% FCS. Halofuginone (50 ng/mi) was added
for 48 hours to some of the cultures. The cells were then lysed with
lysis buffer (10 mvt Tris, pH 7.4, 1% Triton X-100, 50 mrvi NaC1,
0.1 mM Na3V04, 30 m'vi Na4P2O7, 50 mM NaF, 5 mtvi EDTA, 1 mM
PMSF) and 50 jig total cell protein was subjected to 7.5%
SDS-PAGE and blotted onto lmmobilon-P membrane (Miiiipore,
Bedford, MA, USA) [31]. The immunoblots were blocked by
incubation (37°C, 30 mm) in 3% BSA in TBST (20 m'vi Tris-HCI,
pH 7.4, 150 mi NaCi, 0.5% Tween-20), followed by incubation
(16 hr, 4°C) with a monoclonal antibody (1:1000) against phos-
phorylated tyrosine (PY-20; Transduction laboratories, Lexing-
ton, KY, USA). The membrane was washed (x8) in TBST,
followed by incubation (45 mm, 24°C) with horseradish peroxi-
dase-conjugated sheep-anti-mouse IgG (1:3000; Amersham, Little
Chalfout, UK). The immunoreactive proteins were detected by
enhanced chemiluminescence detection system (ECL; Amer-
sham) [311.
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Fig. 1. Effect of halofuginone on proliferation of normal (RMC) and
SV4O transformed (MES) rat mesangial cells. MES (A, B) and RMC (C)
cells were seeded at 1.5 >< iO cells/35 mm dish in medium containing 5%
fetal calf serum (MES) and at 5 >< iO cells/16 mm well of a 24 well plate
in medium containing 10% fetal calf serum (RMCs). Twenty-four hours
after seeding, increasing concentrations (•, 10 ng/ml; , 25 nglml; 0, 50
nglml; A, 75 ng/ml) of halofuginone were added. Control cells (LI) were
maintained without halofuginone. (A) Dose response. Seven days after
seeding the cells were dissociated with STV and counted in a Coulter
counter. (B and C) The time course was the same as A, except that the
cells were dissociated with STV at different intervals after seeding, and
counted in a Coulter counter. Each point represents the mean so from
triplicate cultures.
Evaluation of collagen synthesis
Cells (5 x i0 cells/I 6-mm well) were incubated for 24 hours
with various concentrations of halofuginone in 0.5 ml glutamine-
free DMEM containing 5% FCS, 50 jg/m1 ascorbic acid, 50 g/ml
of aminopropionitrile, and 2 tCi 3H-proline. At the end of
incubation, the medium was decanted and incubated with or
without collagenase for 18 hours, followed by TCA-precipitation.
The amount of radiolabeled collagen was estimated as the differ-
ence between total 3H-proline containing proteins and those left
after collagenase digestion [25, 321.
RNA isolation and Northern blot analysis
Total RNA was isolated using the guanidinium-thiocyanate-
phenol technique [33]. RNA was subjected to 1% agarose dena-
turing gel electrophoresis followed by blotting onto a nylon filter
(GeneScreen Plus; New England Nuclear, Boston, MA, USA).
eDNA probes were labeled using the random primer procedure
[34], with a commercial kit (Boehringer, Germany). Hybridization
was performed overnight at 40°C in a solution containing 10%
dextran sulfate, 1% sodium dodecyl sulfate (SDS), I M NaCl, 40%
formamide and 200 mglml denatured herring sperm DNA. Hy-
bridization was followed by two 30-minute washes in 2 x SSC (1 x
SSC contains 0.15 M NaCI and 0.015 M sodium citrate)-I% SDS,
and two 20-minute washes in 1 x SSC-0.1% SDS. The filters were
exposed to X-ray film (Agfa-Curix, Germany) at —70°C, using
intensifying screens. The amount of RNA loaded per lane was
monitored by methylene blue staining of 18S and 28S RNA.
Each of the above-described studies was performed at least
three times, and the variation between different experiments did
not exceed 20%. Each data point represents the mean SD of
triplicate cultures.
RESULTS
Inhibition of mesangial cell proliferation by halofuginone
Proliferation of mesangial cells (MCs) plays an important role
in pathogenesis of glomerulosclerosis. We investigated the ability
of halofuginone to inhibit the proliferation of actively growing
MCs derived from either primary cultures of rat origin (RMCs) or
the glomerular mouse mesangial cell line MES. Cell proliferation
was evaluated by cell counting at various times after seeding and
maintenance under optimal culture conditions in the absence and
presence of halofuginone. Sparsely seeded MES cells were ex-
posed to 10% FCS in the absence and presence of increasing
concentrations of halofuginone, added 24 hours after seeding.
The cells were dissociated and counted every other day (Fig. 1).
Fifty percent inhibition of MES cell proliferation was obtained at
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25 ng/ml halofuginone, while almost complete inhibition was
observed at 50 nglml (1 x i0 M) (Fig. I A, B). A similar
inhibitory effect was obtained in studies with normal rat mesangial
cells (RMC) derived from primary cultures (Fig. IC). The inhibi-
tion was dose and time dependent. MES cells that were exposed
to low concentrations (10 to 25 ng/ml) of halofuginone on day 2
regained a nearly normal growth rate by day 5 to 7 (Fig. IB). This
is probably due to inactivation of the drug since re-addition of
halofuginone on days 3 and 5 resulted in a sustained inhibition of
cell proliferation. To better evaluate the time needed for the MCs
to recover after removal of the drug, MES cells were exposed to
50 ng/ml halofuginone for 62—72 hours, followed by replacement
of the medium with a halofuginone-free medium. Removal of the
drug resulted in an accelerated growth rate, similar to that of
untreated MES cells (Fig. 2A). This result, as well as the lack of
lactic dehydrogenase release above the basal level detected in
untreated MCs (data not shown), indicate that the antiprolifera-
tive effect of halofuginone is not due to a cytotoxic effect. Similar
results were obtained with primary RMC (Fig. 2B).
We next determined if halofuginone arrested mesangial cell
proliferation at a specific stage of the cell cycle. For this purpose
subconfiuent RMCs were kept in 10% FCS in the absence or
presence of 150 ng/ml halofuginone for 24 hours. The cells were
then harvested, stained with propidium iodide and analyzed by
FACScan. The percentage of cells progressing into G2/M phase
was reduced by halofuginone from 20% to 7%, while the percent-
age of cells in G0/G1 was increased from 38% to 65% in the
absence and presence of halofuginone, respectively. These results
indicate that in the presence of halofuginone, a large proportion
of the MCs are arrested in the GJG1 phase.
Heparin has previously been shown to inhibit MC proliferation
in response to serum and growth promoting factors [III. This
inhibition was attributed to the combined effect of several differ-
ent mechanisms [11]. We compared the inhibitory effect of
halofuginone to that of heparin. Halofuginone already completely
blocked MES cell proliferation at 50 nglml, but there was almost
no inhibition of MC proliferation by heparin up to a concentration
of 100 /.Lg/ml (Fig. 3A). Similarly, only 30 to 40% inhibition of
RMC growth was observed at 50 jig/mI heparin (Fig. 3B), which
is equivalent to about 800 nglml halofuginone when compared on
a molar basis. The relatively low antiproliferative effect of heparin
may be due to the use of a particular heparin preparation.
Significant differences in the biological activities of various
batches of heparin have previously been reported [35].
We investigated the effect of halofuginone on tyrosinc phos-
phorylation in rat MCs. For this purpose, actively growing (10%
FCS) and growth arrested (0.5% FCS) RMCs were pretreated (24
hr, 37°C) with 50 ng/ml halofuginone. The cells were then lysed
and subjected to SDS-PAGE and immunoblot detection of ty-
rosine-phosphorylated proteins [311. Tyrosine phosphorylation of
several cellular proteins (molecular weights 42, 85, 130, 280
kDa) was inhibited in the presence of halofuginone (Fig. 4),
suggesting that the growth inhibitory effect of halofuginone is
associated with a decrease in phosphotyrosine mediated signaling.
Mesangial cells in the glomeruli are located in close proximity
with components of the glomerular basement membrane and
ECM [181. This ECM regulates cell attachment, proliferation and
differentiation and is known to expand during the development of
glomerulosclerosis [15, 18]. We investigated whether MCs seeded
in contact with their own ECM are equally susceptible to the
antiproliferative effect of halofuginone. Figure 5A shows that
halofuginone efficiently inhibited the growth of MES cells seeded
on mesangial ECM, similar to control cells seeded on plastic,
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Fig. 2. Effect of halofuginone removal on rat mesangial cell proliferation.
MES cells (1.5 X iO cells/35-mm dish) .4) or normal RMCs (5 X io
cells/I 6-mm well of a 24-well plate) (B) were seeded and exposed (24 hr
after seeding) to increasing concentrations (, 25 ng/ml; 0, 50 ng/ml; A,
75 ng/ml) of halofuginonc. Control cells (0) were maintained in the
absence of halofuginone. Seventy-two hours after seeding (arrow), the
cultures were washed and fresh medium was added. Some of the cultures
were exposed to halofuginone throughout the experiment (S, A). At
intervals after seeding, the cells were dissociated with STV and counted in
a Coulter counter. Each point represents the mean s from triplicate
cultures.
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Fig. 4. Effect of halofuginone on tyrosine phosphorylation in RMCs.
Subconfluent RMCs were either maintained continuously in DMEM
containing 10% FCS (lanes 1, 2) or growth arrested by 48 hours incubation
in DMEM containing 0.5% FCS (lanes 3 to 5). Halofuginone (50 ng/ml)
was added to some of the cultures (lanes 2 to 4). Twenty-four hours
afterwards some of the growth arrested cultures were stimulated (10 mm)
with 10% serum (lanes 3 and 5). The cells of all cultures were then lysed
and 50 g of the total cellular proteins were separated on 7.5% SDS-
PAGE, immunoblotted with anti-phosphotyrosine antibodies and visual-
ized by ECL, as described in the Methods section. The position of
molecular size standards is indicated.
:: Effect of halofuginone on ECM deposition by mesangial cells
To assess the effect of halofuginone on ECM deposition, RMCs
were seeded at a confluent density in the absence or presence of
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increasing concentrations of halofuginone. Radioactive sulfate
(Na235SO4) or '4C-glycine were added 24 hours after seeding.
Five days afterwards the cell layer was dissolved in order to
expose the underlying ECM The ECM was then digested with
either collagenase (Fig 6 A C) or trypsin (Fig 6 B D) As
demonstrated in Figure 6A sulfate incorporation was reduced by
about 40% in the presence of 200 nglml halofuginone while
glycine incorporation was already inhibited by —70% at 50 ng/ml
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Fig. 3. Inhibitory effect of halofuginone versus heparin on rat mesangial
cells. MES (1.5 X iO cells/dish; .4) and normal RMC (5 X iO cells/well;
B) were exposed to increasing concentrations of halofuginone (•), or
heparin () 24 hours after seeding. Six days afterwards the cells were
dissociated from the plastic and counted in a Coulter counter. Control
cells were maintained in the absence of halofuginone or heparin. Each
point represents the mean so from triplicate cultures.
indicating that the ECM failed to protect the MCs from the
inhibitory effect of halofuginone. Similar results were obtained
with normal rat mesangial cells (Fig. 5B).
halofuginone (Fig 6B) Parallel ECM dishes were subjected to
trypsin digestion followed by J3 scintillation counting (Fig 6 B D)
About 50% and 70% inhibition of sulfate (Fig 6B) and glycint.
(Fig 6D) incorporation into the ECM was observed at 50 ng/ml
halofuginone respectively It should be noted that the inhibition
of ECM deposition by halofuginone was not due to its antiprolit
erative activity since the drug was added to highly confluent
non-dividing RMCs. A profound inhibition of ECM deposition
was supported by microscopic examination of the denuded culture
dishes, revealing very thin or no ECM production in the presence
of halofuginone.
.Effect of halofuginone on collagen type I gene expression and
To evaluate the effect of halofuginone on collagen synthesis,
. .MES cells were incubated with H-proline and halofuginone 0.5
to 5 nglml (10—v to 10 M) for 24 hours. At the end of the
incubation period, collagen csl(l) gene expression (Fig. 7A, upper
panel) and incorporation of radiolabeled proline to collagenase-
digestible proteins (CDP) (Fig. 7A, lower panel) were deter-
mined. Northern blot analysis revealed that halofuginone inhib-
ited collagen al(I) gene expression in a dose dependent manner,
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Fig. 5. Effect of halofuginone on proliferation of rat mesangial cells
seeded on plastic versus ECM. MES (1.5 X iO cells/dish;A) and normal
RMC (5 X io cells/well; B) were seeded into regular tissue culture plastic
(•, ) or plastic coated with a naturally produced mesangial ECM (0, L).
Twenty-four hours after seeding the cells were exposed to increasing
concentrations of halofuginone, and six days afterwards the cells were
dissociated with STV and counted in a Coulter counter. Each point
represents the mean SI) from triplicate cultures.
yielding a nearly maximal effect at a concentration as low as 5
ng/ml (1 x 10 M). The effect of halofuginone (5 ng!ml) on
collagen l(1) gene expression resulted in a 60% inhibition of
incorporated radiolabeled prolinc to CDP (Fig. 7A), with a
minimal inhibitory effect on proline incorporation into non-
collagenase digestible proteins (NCDP) (not shown). Similar
studies performed with normal rat mesangial cells (RMC5) re-
vealed a partial inhibition of collagen al(I) gene expression at 0.5
ng!ml and 5 ng/mI halofuginone with an almost complete inhibi-
tion at 50 ng/ml (1 >< iO Fig. 7B, upper panel). At this
concentration there was a 50% reduction in the amount of
incorporated radiolabeled proline to CDP (Fig. 7B, lower panel).
We have also performed a Northern blot analysis for collagen type
III and found no inhibition by halofuginone (not shown).
DISCUSSION
We have demonstrated that low concentrations (—50 ng/ml) of
halofuginone, similar to those obtained in experimental animals in
vivo [36], almost completely inhibited proliferation of mesangial
cells. This inhibition correlated with a profound suppression of
collagen synthesis and al(I) gene expression by the cells. A similar
pattern of inhibition was observed with both early-passage normal
rat mesangial cells (RMCs) and SV4O-transformed mouse mes-
angial cells (MES) that maintain normal mesangial features [28,
29]. Halofuginone inhibited MC proliferation to a similar extent
regardless of whether the cells were seeded on regular tissue
culture plastic or in contact with the ECM deposited by cultured
mesangial cells. It is therefore conceivable that halofuginone
would exert its inhibitory effect on MCs that are closely associated
with the ECM in the renal microenvironment in vivo. Moreover,
halofuginone markedly inhibited the synthesis and deposition of
ECM by MCs. This effect, in addition to its antiproliferative
activity, may potentiate the efficiency of halofuginone in reducing
the progression of various chronic glomerular diseases.
The addition of halofuginone did not result in cell demise, but
rather in temporary arrest in proliferation as shown by: (i) lack of
lactic dehydrogenase release above the basal level detected in
untreated cultured MCs; (ii) exclusion of trypan blue; and (iii)
reversibility of its antiproliferative effect upon removal of the
compound from the culture media, indicating that inhibition of
cell proliferation was not due to cell toxicity. Likewise, collagen
type I gene expression, which was inhibited by halofuginone, was
resumed in skin fibroblasts after halofuginone removal [25]. We
and others have recently demonstrated the ability of halofuginone
to effectively inhibit vascular smooth muscle cell proliferation in
vitro and intimal hyperplasia in experimental animals [20, 23]. The
efficient antiproliferative activity of halofuginone in both the renal
and vascular systems is most likely due to the similarities between
the processes of atherosclerosis and glomerulosclerosis, and be-
tween vascular smooth muscle cells and renal MCs participating in
these two lesions [14]. Vascular endothelial cells were found to be
less susceptible to the antiproliferative effect of halofuginone as
compared to smooth muscle cells [20] and to MCs, which were the
most sensitive. This differential effect may be beneficial since
intact endothelium is mandatory for normal renal functions.
Previous studies with smooth muscle cells (Choi et al, manuscript
submitted for publication) indicated that inhibition of cell prolif-
eration by halofuginone occurred at a specific arrest point late in
the G1 phase of the cell cycle, about four to six hours prior to S
phase. Similarly, halofuginone treated RMCs were arrested in the
G(,IG1 phase, suggesting that the transition from late G1 to S phase
may be blocked by halofuginone. The antiproliferative effect of
halofuginone was associated with inhibition of tyrosine phosphor-
ylation in RMCs. Of particular interest was the inhibition of
tyrosine phosphorylation of proteins (that is, 42 kDs MAP-kinase
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Fig. 7. Effect of halofuginone on 3H-proline
incorporation and collagen al(I) gene
expression. Upper panel: Collagen al(I) gene
expression by MES (A) and normal (B) rat
mesangial cells (RMCs). Cells were seeded at a
subconfluent density (5 x iO cells/well) and
treated (24 hr, 37°C) with 0.5 to 50 ng/ml (10
to i0 M) halofuginone. At the end of the
incubation period, total RNA was extracted,
subjected to 1% agarose electrophoresis,
blotted onto Nytran membrane and hybridized
with a labeled eDNA probe for collagen type
al(I). The amount of RNA loaded per lane
was monitored by methylene blue staining of
18S RNA. Lower panel: 3H-proline
incorporation. MES (A) and normal (B) RMCs
were seeded at a subconfluent density and
treated (24 hr, 37°C) with increasing
concentrations (0.5 to 50 ag/mI, 10 to 10
M) of halofuginone in glutamine-free DMEM in
the presence of 2 Ci 3}{-proline/well.
Incorporation of praline to collagenase-
digestible proteins (CDP) was determined. The
results are the mean SD of triplicate wells.
and p 90/80 K-H) involved in signal transduction and phosphosylated
in response to cell stimulation by serum [31]. Studies are underway to
better characterize the effect of halofuginone on signal transduction
and cell cycle arrest. Type I collagen production and its presence in
the extracellular milieu may be needed for MCs to reach the late
G1 phase, possibly through interaction with its a2 integrin recep-
tors and the associated signal transduction pathway [37]. Re-
cently, it was reported that fibrillar type I collagen specifically
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Fig. 6. Effect of halofuginone on Na235SO4 and
'4C-glycine incorporation into the ECM
produced by RMCs. RMCs were seeded at a
confluent cell density (5 >< i0 cells/16 mm well
of a 24-well plate). One and three days after
seeding, increasing concentrations of
halofuginone were added together with
Na235SO4 (40 .rCi/ml; A, B) or '4C-glycine (5
LCi/ml; C, D). Control cells were maintained in
the absence of halofuginone. On day 6, the cell
layer was solubilized to expose the underlying
ECM. The ECM was washed with PBS (>3)
and subjected to digestion with collagenase (A,
C) or trypsin (B, D) to determine the amount
of sulfate and glycine incorporated into the
ECM. The results are the mean SD of
triplicate cultures.
0 50 100 200
A B
18s —
500
400
300
200
100
0
500
400
300
200
100
0
Halofuginone, ng/ml
C 0.5 5 C 0.5 5 50
1568 t'/agler ci al: Inhibition of mesangial cell proliferation
regulates early integrin signaling that may lead to inhibition of
SMC proliferation, while monomer collagen supports smooth
muscle cell proliferation [38]. Cell proliferation may thus be
regulated in different ways by structurally distinct forms of type I
collagen and hence by compounds such as halofuginone that
affect the synthesis of monomeric collagen at the transcriptional
level [25]. The significance of collagen in the control of cell
proliferation was also demonstrated by showing that anti-sense to
collagen type IV inhibited proliferation of glomerular endothelial
cells [39].
Remodeling of the mesangial matrix is a final common pathway
towards glomerular destruction in a variety of chronic progressive
glomerular diseases [15, 18]. Increase in mesangial cellularity and
ECM, in particular in collagen types I, III and IV, are prominent
histological abnormalities encountered in renal fibrosis, both in
experimental animal models and in humans [10, 16—19, 40]. It is
now well recognized that the ECM is not simply an inert
scaffolding that stabilizes the physical structure of tissues; rather,
it plays an important role in the determination of cell shape, gene
expression and proliferative responses of the cells that are in
contact with it [41, 42]. We have previously demonstrated that
halofuginone efficiently inhibits fibrosis in several animal models
[20, 23—26], most likely via specific inhibition of collagen al(I)
synthesis and gene expression [21, 22]. This type of collagen is a
major constituent of the ECM upon which cells migrate, prolif-
erate and differentiate in vivo. In previous studies we and others
have demonstrated that halofuginone had no effect on the
synthesis and/or gene expression of collagen types a2(I), II and III
[21, 23]. There was also no effect on collagen types IV (Nagler et
al, manuscript submitted) and X [36], as revealed by immuno-
staining and Northern blot analysis, respectively. Similarly, we
evaluated the effect of halofuginone on collagen type III gene
expression by rat mesangial cells and found no inhibition (not
shown).
It should be noted that the inhibition of ECM deposition by
halofuginone was not due to its antiproliferative activity since the
drug was effective when added to highly confluent, nondividing
RMCs. Our results suggest that the effect of halofuginone on
ECM deposition by RMCs is due to both its known inhibitory
effect on collagen synthesis [21, 22], and to an effect on the
deposition and/or assembly of other macromolecular constituents
in intact ECM. It is conceivable that by inhibiting collagen type I
synthesis, halofuginone interferes with the assembly of other
ECM macromolecules (such as heparan sulfate proteoglycans)
that are known to specifically interact with collagen (through its
heparin binding domain) [43] and which form the supramolecular
structure comprising the ECM. This is supported by the marked
reduction in the amount of ECM-incorporated sulfate labeled
material in the presence of halofuginone, since inorganic sulfate is
incorporated primarily into sulfated glycosaminoglycans and not
into collagen. Unlike sulfate, glycine is incorporated primarily to
collagen and to a lesser extent into non-collagenous components
of the ECM. This was reflected by the profound reduction in
glycine incorporation into collagenase digestible proteins (CDP)
already at 50 ng/ml halofuginone (Fig. 6C). It can thus be
concluded that exposure to halofuginone results in a substantial
inhibition of matrix deposition as revealed by phase microscopy
and a profound decrease in the synthesis of both CDP and NCDP.
In accordance, measurements of glycine and sulfate incorporation
into total tricarboxylic acid precipitable cellular proteins revealed
little or no inhibition by halofuginone. In a preliminary experi-
ment RMCs were plated into dishes coated with native ECM or
fibrillar type I collagen, rather than on regular tissue culture
plastic. Under these conditions, halofuginone exerted only a small
inhibitory effect on the incorporation of Na235SO4 or 14C-glycine
into the ECM, suggesting that the inhibition of ECM deposition
by halofuginone is in fact due to its inhibition of collagen type I
synthesis.
It was recently reported that the Spi transcription factor
regulates the expression of the collagen type al(I) gene [44] and
hence may be involved in tissue fibrosis. It was also shown that
expression of the zinc-finger transcription factor egr-1 is an
essential part of the mitogenic signal transduction cascade in
cultured MCs and is closely correlated with their proliferation
[451. It is therefore of interest to investigate whether expression of
Spi and egr-1 by MCs is suppressed by halofuginone. Although
we attribute the antiproliferative activity of halofuginone to its
inhibition of collagen csl(I) gene expression, the exact mechanism
of action (that is, binding to cell surface receptors, internalization,
interaction with intracellular mediators) still has to be elucidated.
Exhaustive attempts to define substances able to inhibit mes-
angial proliferation and thereby progression to end-stage renal
disease [3] have proven unrewarding. Only a small number of
substances with this capability have been defined, of which only
heparin has reached clinical trials in humans, and has not showed
a major impact on the evolution of renal lesions [12, 13]. The fact
that halofuginone is non-toxic and can be administered both
locally and orally [20, 23, 24, 26] makes it a likely candidate for
further studies in animal models of glomerular diseases. Its ability
to suppress mesangial cell proliferation, collagen type I synthesis,
and matrix expansion may provide a useful means for early
therapeutic intervention, halting the progression of glomerular
and interstitial fibrosis before it reaches irreversible stages.
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